Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

PURPOSE Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during
allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is …

Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality.
It is treated with bone marrow transplantation (BMT) for those with fully matched donors, or …

The key immunologic signatures associated with clinical outcomes after posttransplant
cyclophosphamide (PTCy)-based HLA-haploidentical (haplo) and HLA-matched bone …

Haploidentical stem cell transplantation (haplo-SCT), an alternative donor source, offers a
curative therapy for patients with acute myeloid leukemia (AML) who are transplant …

Optimal donor selection is fundamental to successful allogeneic hematopoietic cell
transplantation (HCT), and donor age influences survival after both matched unrelated …

Allogeneic hematopoietic cell transplantation (alloHCT) often represents the only curative
treatment for various malignant and nonmalignant disorders. Initially, the only suitable …

Blood or marrow transplantation (BMT) outcomes using haploidentical donors (Haplo) and
posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) …

In patients without a matched sibling donor (MSD) or well-matched unrelated donor (MUD),
hematopoietic cell transplantation (HCT) can still be successful when using an HLA …

We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation
(HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant …